Id |
Subject |
Object |
Predicate |
Lexical cue |
T146 |
73-116 |
Sentence |
denotes |
Double-blind RCT (NCT04257656, recruiting). |
T147 |
117-206 |
Sentence |
denotes |
Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28. |
T148 |
207-289 |
Sentence |
denotes |
• Comparison of remdesivir vs. placebo in patients with mild to moderate COVID-19. |
T149 |
290-333 |
Sentence |
denotes |
Double-blind RCT (NCT04252664, recruiting). |
T150 |
334-407 |
Sentence |
denotes |
Primary endpoint: time to clinical recovery in hours (follow-up 28 days). |
T151 |
408-495 |
Sentence |
denotes |
• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. |
T152 |
496-537 |
Sentence |
denotes |
Open-label RCT (NCT04252664, recruiting). |
T153 |
538-645 |
Sentence |
denotes |
Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days). |
T154 |
646-735 |
Sentence |
denotes |
• Comparison of remdesivir vs. local standard of care in patients with moderate COVID-19. |
T155 |
736-777 |
Sentence |
denotes |
Open-label RCT (NCT04292730, recruiting). |
T156 |
778-824 |
Sentence |
denotes |
Primary endpoint: discharged status at day 14. |
T157 |
825-890 |
Sentence |
denotes |
• Comparison of remdesivir vs. placebo in patients with COVID-19. |
T158 |
891-934 |
Sentence |
denotes |
Double-blind RCT (NCT04280705, recruiting). |
T159 |
935-1006 |
Sentence |
denotes |
Primary endpoint: severity rating on a 8-point ordinal scale at day 15. |
T160 |
1007-1122 |
Sentence |
denotes |
• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. |
T161 |
1123-1181 |
Sentence |
denotes |
Open-label adaptive RCT (NCT04321616, not yet recruiting). |
T162 |
1182-1252 |
Sentence |
denotes |
Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks). |
T163 |
1253-1422 |
Sentence |
denotes |
• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. |
T164 |
1423-1476 |
Sentence |
denotes |
Double-blind, adaptive RCT (NCT04315948, recruiting). |
T165 |
1477-1548 |
Sentence |
denotes |
Primary endpoint: severity rating on a 7-point ordinal scale at day 15. |